^
    Back
    Association details:
    Biomarker:FGFR3-TACC3 F17T8
    Cancer:Cervical Cancer
    Drug:fexagratinib (ABSK091) (FGFR inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Molecular analysis for therapy choice (MATCH) arm W: Phase II study of AZD4547 in patients with tumors with aberrations in the FGFR pathway.

    Published date:
    05/16/2018
    Excerpt:
    All pts with PR had tumors harboring FGFR fusions; one with urothelial transitional cell carcinoma (FGFR3-TACC3 F17T8) and the other with squamous cell carcinoma of cervix (FGFR3-TACC3 F17T11)
    DOI:
    10.1200/JCO.2018.36.15_suppl.2503
    Trial ID:
    NCI-MATCH
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    J Clin Oncol
    Title:

    Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

    Excerpt:
    One patient with cervical cancer harboring an FGFR3-TACC3.F17T8 gene fusion underwent prior surgery and radiation therapy and received 2 months of cisplatin approximately 8.5 years before enrollment….Clinical Characteristics and Genomic Aberrations of the Patients Who Achieved PR (n = 4) and SD for > 6 months (n = 3)
    DOI:
    10.1200/JCO.19.02630